1-(4-氟苯基)-1H-吡咯-4-甲醛 | 890652-03-6

• 物质功能分类: 医药中间体 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-氟苯基)-1H-吡咯-4-甲醛
• 中文别名: 1-(4-氟苯基)吡唑-4-甲醛；1-(4-氟苯基)-1H-吡唑-4-甲醛
• 英文名称: 1-(4-fluorophenyl)-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-(4-fluorophenyl)pyrazole-4-carbaldehyde
• CAS: 890652-03-6
• 化学式: C₁₀H₇FN₂O
• mdl: MFCD05864516
• 分子量: 190.177
• InChiKey: OTZFOHVFXOKYGB-UHFFFAOYSA-N

物化性质

• 沸点：
  306.5±22.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  对水稍有危害，请勿在无政府许可的情况下将材料排放到环境中。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 储存条件：
  存放于密闭、阴凉、干燥处

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-(4-Fluorophenyl)pyrazole-4-carbaldehyde
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-(4-Fluorophenyl)pyrazole-4-carbaldehyde
Ingredient name:
CAS number: 890652-03-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H7FN2O
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)-1H-吡咯-4-甲醛 在 盐酸羟胺 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以84%的产率得到1-(4-氟苯基)-1H-吡唑-4-甲腈
  参考文献：
  名称：

  新的吡唑衍生物5- [1-（4-氟苯基）-1H-吡唑-4-基] -2H-四唑：合成和一些生物学活性的评估。

  摘要：

  化合物的分子修饰和合成对于发现具有理想药理学和毒性特征的药物至关重要。针对吡唑化合物的解热，镇痛和抗炎作用，本研究试图评估新型吡唑衍生物5- [1]的镇痛，抗炎和血管舒张作用，以及作用机理。 -（4-氟苯基）-1H-吡唑-4-基] -2H-四唑。在醋酸引起的腹部扭动试验中，用5- [1-（4-氟苯基）-1H-吡唑-4-基] -2H-四唑治疗可减少腹部扭动，而在福尔马林试验中，5- [1- （4-氟苯基）-1H-吡唑-4-基] -2H-四唑减少了对神经源性疼痛和炎症性疼痛的舔times时间，而没有表现出任何抗伤害感受的效果，如甩尾试验中所揭示的那样。5- [1-（4-氟苯基）-1H-吡唑-4-基] -2H-四唑在角叉菜胶引起的胸膜炎试验中也减少了角叉菜胶引起的爪水肿和细胞迁移。如分离器官的模型所证实，5- [1-（4-氟苯基）-1H-吡唑-4-基] -2H-四唑显示出血管舒张作用被Nomega-硝基-1-精氨酸甲酯1H减弱-[1

  DOI：

  10.1111/cbdd.12838
• 作为产物：
  描述：

  1,4-二氟苯 、 1H-吡唑-4-甲醛 在 tetrabutylammonium tetrafluoroborate 、 溶剂黄146 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙腈 为溶剂， 反应 36.0h， 以90%的产率得到1-(4-氟苯基)-1H-吡咯-4-甲醛
  参考文献：
  名称：

  未活化的芳基氟化物在常温和无碱条件下的电光催化SN Ar反应。

  摘要：

  证明了在室温下没有强碱的未活化芳基氟化物的电光催化SN Ar反应。

  DOI：

  10.1002/anie.201909983

文献信息

• [EN] SYNTHESIS OF AGELADINE A AND ANALOGS THEREOF<br/>[FR] SYNTHÈSE D'AGÉLADINE A ET D'ANALOGUES DE CELLE-CI
  申请人：UNIV MACQUARIE

  公开号：WO2009152584A1

  公开（公告）日：2009-12-23

  The invention describes a one pot process for synthesizing a compound of structure (I), or a tautomer thereof. A compound of structure (II), or a tautomer thereof, and an aldehyde of structure RdCHO are condensed to form a condensation product. The resulting condensation product is then oxidized in the same reaction mixture to produce the compound of structure (I) or a tautomer thereof.

  该发明描述了一种一锅法合成结构式(I)化合物或其同分异构体的过程。将结构式(II)化合物或其同分异构体与RdCHO结构的醛缩合形成缩合产物。然后将所得缩合产物在同一反应混合物中氧化，以产生结构式(I)化合物或其同分异构体。
• Palladium Catalysis Enables Benzylation of α,α‐Difluoroketone Enolates
  作者：Ming‐Hsiu Yang、Jordan R. Hunt、Niusha Sharifi、Ryan A. Altman

  DOI：10.1002/anie.201604149

  日期：2016.7.25

  A palladium‐catalyzed decarboxylative benzylation reaction of α,α‐difluoroketone enolates is reported, in which the key C(α)−C(sp3) bond is generated by reductive elimination from a palladium intermediate. The transformation provides convergent access to α‐benzyl‐α,α‐difluoroketone‐based products, and should be useful for accessing biological probes.

  据报道，钯催化的α，α-二氟酮烯酸酯的脱羧苄基化反应，其中关键的C（α）-C（sp 3）键是通过从钯中间体中进行还原性消除而生成的。这种转化提供了对基于α-苄基-α，α-二氟酮的产品的集中访问，并且对于访问生物探针应该是有用的。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Electrophotocatalysis with a Trisaminocyclopropenium Radical Dication
  作者：He Huang、Zack M. Strater、Michael Rauch、James Shee、Thomas J. Sisto、Colin Nuckolls、Tristan H. Lambert

  DOI：10.1002/anie.201906381

  日期：2019.9.16

  electrophotocatalytic oxidation platform. This chemistry employs a trisaminocyclopropenium (TAC) ion catalyst, which is electrochemically oxidized to form a cyclopropenium radical dication intermediate. The radical dication undergoes photoexcitation with visible light to produce an excited-state species with oxidizing power (3.33 V vs. SCE) sufficient to oxidize benzene and halogenated benzenes via single-electron

  可见光光催化和电催化是促进化学反应的两种强大策略。在这里，这两种模式结合在电光催化氧化平台中。该化学过程采用三氨基环丙烯 (TAC) 离子催化剂，通过电化学氧化形成环丙烯自由基阳离子中间体。自由基阳离子在可见光下进行光激发，产生具有氧化能力（3.33 V vs. SCE）的激发态物质，足以通过单电子转移（SET）氧化苯和卤代苯，从而导致 CH/NH 与唑类偶联。提供了光激发物质的强氧化行为的基本原理，同时通过顺式2,6-二甲基哌啶部分的特定构象合理化了催化剂的稳定性。
• Complete assignment of NMR data of 22 phenyl-1<i>H</i> -pyrazoles' derivatives
  作者：Aline Lima de Oliveira、Carlos Henrique Alves de Oliveira、Laura Maia Mairink、Francine Pazini、Ricardo Menegatti、Luciano Morais Lião

  DOI：10.1002/mrc.2773

  日期：2011.8

  Complete assignment of 1H and 13C NMR chemical shifts and J(1H/1H and 1H/19F) coupling constants for 22 1‐phenyl‐1H‐pyrazoles' derivates were performed using the concerted application of 1H 1D and 1H, 13C 2D gs‐HSQC and gs‐HMBC experiments. All 1‐phenyl‐1H‐pyrazoles' derivatives were synthesized as described by Finar and co‐workers. The formylated 1‐phenyl‐1H‐pyrazoles' derivatives were performed under

  22 1-苯基-1H-吡唑衍生物的 1H 和 13C NMR 化学位移和 J（1H/1H 和 1H/19F）耦合常数的完整分配是使用 1H 1D 和 1H、13C 2D gs-HSQC 的协同应用完成的和 gs-HMBC 实验。所有 1-苯基-1H-吡唑衍生物均按照Finar 及其同事的描述合成。甲酰化 1-苯基-1H-吡唑衍生物在达夫条件下进行。版权所有 © 2011 John Wiley & Sons, Ltd.